A Collection of Hematology & Oncology Articles
The practice of oncology and hematology is in constant evolution. These articles highlight some of the most notable advancements and discoveries in the modern medical world. We invite you to use this site frequently and collaborate with medical professionals across the globe.
Welcome
At Florida Cancer Specialists & Research Institute (FCS), our physicians and advanced practice providers are deeply vested in clinical research to provide the most cutting-edge treatment options available to our patients. In our own practices we are fortunate to offer over 300 clinical trials across 37 locations including 3 dedicated Phase 1 Drug Development Units. We value every opportunity to share best practices and the latest research both within and outside of our institution. We welcome you to use this collection as a resource to support your own research and understanding as we strive together to advance cancer care one step at a time.
Recent Articles
Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Use of recombinant factor VII slowed the progression of hematomas but did not improve cognitive function and increased the risk of thrombosis.
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal
DON’T… more toxic, no benefit.
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Pirtobrutinib demonstrated superiority over bendamustine rituximab in IRC assessed progression free survival (PFS) in treatment naïve CLL/SLL, with a 24 month PFS rate of 93.4% versus 70.7%. Overall survival trends favored pirtobrutinib, despite the study design allowing for crossover. Who would have thought this was coming????
Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma—PUMP-2 Trial
With the addition of intrahepatic chemotherapy, median overall survival was 22.3 months. One year overall survival reached 80.0%, exceeding the historical control rate of 47%, while three year overall survival was 31.5%. For patients who can tolerate this approach, it appears to be a reasonable and potentially worthwhile option.
Music Therapy Versus Cognitive Behavioral Therapy via Telehealth for Anxiety in Survivors of Cancer: A Randomized Clinical Trial
Music therapy is noninferior to CBT for anxiety in survivors of cancer. Music therapy was found to be noninferior to cognitive behavioral therapy for anxiety among cancer survivors. Both telehealth interventions produced clinically meaningful and durable improvements in anxiety. Should we hire musicians?
Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial
A B7 homolog 3–directed antibody-drug conjugate, demonstrated an overall response rate of 48.2%, with a median duration of response of 5.3 months, and a median progression-free survival of 4.9 months. The 9-month overall survival estimate was 59.1%. This represents another ADC with promising activity, although interstitial lung disease remains a concern, occurring in approximately 12% of patients.
Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors
A promising anti TP53 agent demonstrated an overall response rate of 20%, increasing to 30% in patients with KRAS wild type disease. Nausea and vomiting were the most commonly reported adverse events. While early, this agent may warrant continued attention as additional data emerge.
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
FCS Physician Focus
Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer
FCS medical oncologist and hematologist Ernesto Bustinza-Linares, MD has co-authored an abstract published in the American Society of Clinical Oncology Journal, JCO Precision Oncology, that uncovers a new testing method to determine personalized care options for patients with metastatic non-small cell lung cancer (NSCLC). The abstract’s authors address the limitations of existing guidelines that recommend checkpoint immunotherapy, sometimes in combination with chemotherapy, for treating NSCLC, which often discounts patient variability and immune factors. The findings from the study show that by incorporating additional plasma proteome-based testing, combined with the standard protein inhibitor testing, clear differences in patient outcomes were observed after applying targeted treatments based on the testing results.
Florida Cancer Specialists & Research Institute